Key Publications
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N Engl J Med. 2006 Dec 7;355(23):2408-17.
Druker BJ, Guilhot F, O'Brien SG, et al.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
N Engl J Med. 2006 Jun 15;354(24):2542-51.
Kantarjian H, Giles F, Wunderle L, et al.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med. 2006 Jun 15;354(24):2531-41.
Talpaz M, Shah NP, Kantarjian H, et al.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med. 2003 Mar 13;348(11):994-1004.
O'Brien SG, Guilhot F, Larson RA, et al.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med. 2002 Feb 28;346(9):645-52.
Kantarjian H, Sawyers C, Hochhaus A, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med. 2001 Apr 5;344(14):1038-42.
Druker BJ, Sawyers CL, Kantarjian H, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med. 2001 Apr 5;344(14):1031-7.
Druker BJ, Talpaz M, Resta DJ, et al.
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Lancet. 1998 Oct 3;352(9134):1087-92.
Gratwohl A, Hermans J, Goldman JM, et al.
Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
Blood. 2007 Feb 22; [Epub ahead of print]
Hehlmann R, Berger U, Pfirrmann M, et al.
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.
Guilhot F, Apperley J, Kim DW, et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Blood. 2007 Apr 15;109(8):3496-9. Epub 2006 Dec 27.
Picard S, Titier K, Etienne G, et al.
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
Blood. 2007 Feb 15;109(4):1782-9. Epub 2006 Oct 24.
Oehler VG, Gooley T, Snyder DS, et al.
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Blood. 2007 Jan 15;109(2):500-2. Epub 2006 Sep 21.
Giles FJ, Cortes J, Jones D, Bergstrom D, et al.
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18.
Kantarjian HM, Talpaz M, O'Brien S, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood. 2006 Sep 15;108(6):1809-20. Epub 2006 May 18. Review.
Baccarani M, Saglio G, Goldman J, et al.
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Blood. 2006 Sep 1;108(5):1478-84. Epub 2006 Apr 20.
Roy L, Guilhot J, Krahnke T, et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood. 2006 Jul 1;108(1):28-37. Epub 2006 Mar 7.
Hughes T, Deininger M, Hochhaus A, et al.
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Blood. 2005 Nov 1;106(9):2969-76. Epub 2005 Jul 5.
Crawley C, Szydlo R, Lalancette M, et al.
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Blood. 2004 Dec 15;104(13):4245-51. Epub 2004 Aug 19.
Baccarani M, Martinelli G, Rosti G, et al.
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood. 2004 Apr 15;103(8):2873-8. Epub 2003 Dec 24.
Kantarjian H, Talpaz M, O'Brien S, et al.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Blood. 2003 Dec 15;102(13):4298-305. Epub 2003 Aug 21.
Gardembas M, Rousselot P, Tulliez M, et al.
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood. 2003 Jan 15;101(2):473-5. Epub 2002 Sep 12.
Kantarjian HM, Talpaz M, O'Brien S, et al.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell. 2005 Feb;7(2):129-41.
Weisberg E, Manley PW, Breitenstein W, et al.
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science.
2004 Jul 16;305(5682):399-401.
Shah NP, Tran C, Lee FY,et al.
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Science.
2000 Sep 15;289(5486):1938-42.
Schindler T, Bornmann W, Pellicena P, et al.
Dynamics of chronic myeloid leukaemia.
Nature. 2005 Jun 30;435(7046):1267-70.
Michor F, Hughes TP, Iwasa Y, et al.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med. 1996 May;2(5):561-6.
Druker BJ, Tamura S, Buchdunger E, et al.
